WTAP weakens oxaliplatin chemosensitivity of colorectal cancer by preventing PANoptosis

Yue-Tao Tan,Ting Li,Ruo-Bing Wang,Ze-Kun Liu,Meng-Yao Ma,Ren-Ze Huang,Hai-Yu Mo,Shu-Yu Luo,Jin-Fei Lin,Rui-Hua Xu,Huai-Qiang Ju
DOI: https://doi.org/10.1016/j.canlet.2024.217254
2024-11-01
Abstract:As the most abundant post-transcriptional modification in eukaryotes, N6-methyladenosine (m6A) plays a crucial role in cancer cell proliferation, invasion and chemoresistance. However, its specific effects on chemosensitivity to oxaliplatin-based regimens and the impact of these drugs on m6A methylation levels in colorectal cancer (CRC) remain largely unexplored. In this study, we demonstrated that the m6A methyltransferase Wilms tumor 1-associating protein (WTAP) weakens oxaliplatin chemosensitivity in HCT116 and DLD1 cells. Mechanistically, oxaliplatin treatment upregulated WTAP expression, preventing multiple forms of cell death simultaneously, a process known as PANoptosis, by decreasing intracellular oxidative stress through maintaining the expression of nuclear factor erythroid-2-related factor 2 (NRF2), a major antioxidant response element, in an m6A-dependent manner. In addition, high WTAP expression in CRC patients is associated with a poor prognosis and reduced benefit from standard chemotherapy by clinical data analysis of The Cancer Genome Atlas (TCGA) database and patient cohort study. These findings suggest that targeting WTAP-NRF2-PANoptosis axis could enhance the antitumor efficacy of oxaliplatin-based chemotherapy in CRC treatment.
What problem does this paper attempt to address?